{"id":391696,"date":"2014-04-04T00:00:00","date_gmt":"2014-04-04T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbascv0114-biopharma-chronic-heart-failure-decision-base-us-2014\/"},"modified":"2026-03-31T09:05:34","modified_gmt":"2026-03-31T09:05:34","slug":"dbascv0114-biopharma-chronic-heart-failure-decision-base-us-2014","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbascv0114-biopharma-chronic-heart-failure-decision-base-us-2014\/","title":{"rendered":"Chronic Heart Failure | Decision Base | US | 2014"},"content":{"rendered":"<p><em>In the Era of Generic Cardiovascular Agents, Can Emerging Therapies Achieve Substantial Clinical Differentiation to Gain Widespread Use?<\/em><\/p>\n<p>Chronic heart failure (CHF) describes the long-term management of heart failure outside the hospital setting. CHF patients are subject to high rates of mortality and morbidity. Frequent readmissions to the hospital mean that CHF also represents a significant healthcare burden. First-line treatment of CHF usually involves use of an angiotensin-converting enzyme (ACE) inhibitor, oral beta blocker, and oral diuretic. The addition of second- or third-line agents is often dictated by patient symptoms and disease severity. The CHF segment boasts a healthy pipeline, with numerous therapies in various states of development. Furthermore, a variety of therapeutic strategies are being explored that range from novel nonsteroidal mineralocorticoid antagonists to allogeneic stem cell therapies.<\/p>\n","protected":false},"template":"","class_list":["post-391696","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-chronic-heart-failure","biopharma-therapy-areas-heart-failure","biopharma-geography-us","biopharma-date-574"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391696","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391696\/revisions"}],"predecessor-version":[{"id":394819,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391696\/revisions\/394819"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391696"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}